The Recall Desk

State

New Mexico product recalls

73,912 recalls have nationwide distribution and so reach New Mexico. 3,639 additional recalls listed New Mexico specifically in their distribution scope.

What the numbers show

Total
3,639
Critical
745
Severe
816
Most recent
2026-11-11

Of the 3,639 recalls naming New Mexico we have scored against our rubric, 745 (20%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 816 (22%) are Severe.

These figures cover only the 3,639 recalls whose distribution notice names New Mexico specifically. The 73,912 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

57226–57250 of 77551

  • SevereFDA (Drugs)·D-759-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levomefolate Calcium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levomefolate Calcium API due to potential penicillin cross-contamination from inadequate facility separation. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Levomefolate Calcium or L-5-Methyltetrahydrofolate Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-733-2015·2015-04-29

    Attix Pharmaceuticals Recalls Indomethacin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Indomethacin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Indomethacin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-748-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lansoprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of lansoprazole active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Lansoprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-494-2015·2015-04-29

    Attix Pharmaceuticals Recalls 3,4-Diaminopyridine Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling 3,4-Diaminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    3,4-Diaminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-621-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-739-2015·2015-04-29

    Attix Pharmaceuticals Recalls Itraconazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling itraconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Itraconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-547-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromfenac Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bromfenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bromfenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-928-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thyroid Porcine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thyroid Porcine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Thyroid Porcine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-932-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tobramycin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Tobramycin Base distributed between January 2012 and February 2015 due to potential penicillin cross-contamination during repackaging.

    Product
    Tobramycin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-898-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sodium Gluconate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sodium Gluconate active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Sodium Gluconate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-525-2015·2015-04-29

    Artesunate API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Artesunate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Artesunate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-855-2015·2015-04-29

    Prednisolone Acetate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Prednisolone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Prednisolone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-915-2015·2015-04-29

    Attix Pharmaceuticals Recalls Taurolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of taurolidine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Taurolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-829-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paclitaxel API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Paclitaxel Semi-Synthetic active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Paclitaxel Semi-Synthetic active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-645-2015·2015-04-29

    Attix Pharmaceuticals Recalls Droperidol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Droperidol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Droperidol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-738-2015·2015-04-29

    Attix Pharmaceuticals Recalls Isoxsuprine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Isoxsuprine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Isoxsuprine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-889-2015·2015-04-29

    Attix Pharmaceuticals Recalls Secretin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Secretin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Secretin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-828-2015·2015-04-29

    Attix Pharmaceuticals Recalls Oxcarbazepine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling oxcarbazepine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Oxcarbazepine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-959-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zolmitriptan Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling zolmitriptan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Zolmitriptan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-509-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amantadine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amantadine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amantadine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-843-2015·2015-04-29

    Pioglitazone HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Pioglitazone HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pioglitazone HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-840-2015·2015-04-29

    Attix Pharmaceuticals Recalls Phenoxybenzamine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Phenoxybenzamine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Phenoxybenzamine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-692-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formoterol Fumarate Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formoterol Fumarate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Formoterol Fumarate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide